Anemia of Chronic Disease: Reading the Iron-Inflammation Bind

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

Anemia of chronic disease is associated with inflammation-induced hepcidin rise that traps iron in storage, creating a distinct pattern: low serum iron and transferrin saturation (typically 20–45%), low-normal TIBC, and normal-to-high ferritin. Distinguishing this from iron deficiency may help support appropriate management—addressing underlying inflammation first—to restore oxygen delivery and functional capacity.

Read more →

Understand what your iron blood health results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

Anemia of chronic disease and the iron-inflammation bind

Testing for anemia of chronic disease shows how ongoing inflammation restricts red blood cell building. These biomarkers reveal whether iron is available, how the body is transporting and storing it, and how the bone marrow is responding. Serum iron and transferrin saturation reflect circulating iron ready for hemoglobin assembly. Ferritin shows stored iron inside cells and often rises with inflammation (acute-phase storage protein). Transferrin falls when the liver shifts away from iron transport (negative acute-phase protein). Hepcidin, made by the liver, is the key hormonal brake that traps iron in macrophages and blocks gut absorption (iron-regulatory peptide). The soluble transferrin receptor mirrors cellular iron demand and marrow uptake, helping distinguish true iron lack from iron lock-up (sTfR). Hemoglobin and the reticulocyte count capture marrow output, while erythropoietin indicates the kidney’s red cell growth signal (EPO). Inflammation markers such as C-reactive protein trace the cytokine drive. Together, these tests map an iron-restricted state created by inflammation and clarify the biological bottlenecks that can be addressed.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Why an iron-plus-inflammation panel matters

Anemia of chronic disease (ACD) reflects how inflammation rewires iron handling and red‑blood‑cell production across the body. Immune signals raise hepcidin, trapping iron in storage and away from marrow, while blunting erythropoietin and shortening red‑cell lifespan. The result is fewer, smaller oxygen carriers, with effects on energy, cognition, exercise tolerance, and organ perfusion. Key labs map this physiology. Hemoglobin is typically about 13.5–17.5 in men and 12.0–15.5 in women; people tend to feel best in the mid‑to‑upper normal range. Ferritin, an iron‑storage marker, is often roughly 30–300 and “optimal” is not at the very bottom. Serum iron commonly sits near 60–170, total iron‑binding capacity around 250–450, and transferrin saturation roughly 20–45%, with comfort often near the middle. The CRP/albumin ratio is usually very low in health (often below 0.1); lower is better because it signals minimal inflammation and preserved protein status. When values fall, the pattern of ACD emerges: hemoglobin drops, serum iron and saturation are low, TIBC is low‑normal (unlike classic iron deficiency, where it rises), and ferritin is normal or high because iron is sequestered, not absent. The CRP/albumin ratio climbs as CRP rises and albumin falls. Fatigue, shortness of breath on exertion, pallor, and brain fog are common; children may show reduced growth or school performance, and pregnancy’s normal hemodilution can mask severity. Big picture, these tests connect inflammation, liver protein synthesis, kidney erythropoietin signaling, marrow function, and iron traffic. Tracking them helps distinguish ACD from true iron lack, gauge inflammatory burden, and understand long‑term risks like reduced functional capacity, worsened cardiovascular strain, and poorer outcomes in chronic disease.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What an ACD workup can clarify — and what it can't

Anemia of chronic disease (ACD) blood testing provides insight into how your body manages iron and red blood cell production in the context of long-term inflammation or illness. This matters because red blood cells carry oxygen to every tissue, supporting energy, metabolism, brain function, heart health, and immune defense. At Superpower, we assess hemoglobin, ferritin, iron, total iron-binding capacity (TIBC), percent saturation, and the CRP/albumin ratio to understand this complex interplay. Hemoglobin is the main protein in red blood cells that transports oxygen. Ferritin reflects your body’s iron stores. Iron measures the circulating iron available for making new red blood cells. TIBC indicates the blood’s capacity to bind iron, while percent saturation shows how much of that capacity is actually filled. The CRP/albumin ratio is a marker of inflammation, with higher values suggesting more active or chronic inflammatory processes. In ACD, inflammation disrupts normal iron handling. Hemoglobin levels are often low, signaling reduced oxygen-carrying capacity. Ferritin may appear normal or high, as iron becomes trapped in storage and unavailable for use. Blood iron is typically low, while TIBC is also low or normal—unlike other forms of anemia, where TIBC usually rises. Percent saturation drops, reflecting less iron available for red blood cell production. An elevated CRP/albumin ratio confirms the presence of inflammation, which is central to ACD.Interpretation of these markers can be influenced by factors such as age, pregnancy, acute illness, chronic disease, certain medications, and laboratory methods. These variables can shift results, so context is essential for accurate understanding.

Frequently Asked Questions

References

  1. Weiss G, Goodnough LT (2005). Anemia of chronic disease. *The New England Journal of Medicine*, *352*(10), 1011-1023. https://doi.org/10.1056/NEJMra041809
  2. Ganz T (2019). Anemia of inflammation. *The New England Journal of Medicine*, *381*(12), 1148-1157. https://doi.org/10.1056/NEJMra1804281
  3. Ganz T (2003). Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. *Blood*, *102*(3), 783-788. https://doi.org/10.1182/blood-2003-03-0672
  4. Punnonen K, Irjala K, Rajamäki A (1997). Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. *Blood*, *89*(3), 1052-1057. https://pubmed.ncbi.nlm.nih.gov/9028338/
  5. Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, Chamberlin JS, Sullivan LA, Bray KR, Southwick PC (2011). Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. *American Journal of Hematology*, *86*(11), 923-927. https://doi.org/10.1002/ajh.22108

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey